Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging

Sungheon Kim, L. A. Loevner, Harry Quon, A. Kilger, E. Sherman, G. Weinstein, A. Chalian, H. Poptani

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of Ktrans, ve, and τi. Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment Ktrans value of the CR group (0.64 ± 0.11 minutes-1, n = 24) was significantly higher (P = .001) than that of the PR (0.21 ± 0.05 minutes-1, n = 9) group. No significant difference was found in other pharmacokinetic model parameters: ve and τi, between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P = .276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC.

Original languageEnglish (US)
Pages (from-to)262-268
Number of pages7
JournalAmerican Journal of Neuroradiology
Volume31
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Tumor Microenvironment
Magnets
Residual Neoplasm
Therapeutics
Permeability
Pharmacokinetics
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. / Kim, Sungheon; Loevner, L. A.; Quon, Harry; Kilger, A.; Sherman, E.; Weinstein, G.; Chalian, A.; Poptani, H.

In: American Journal of Neuroradiology, Vol. 31, No. 2, 02.2010, p. 262-268.

Research output: Contribution to journalArticle

Kim, Sungheon ; Loevner, L. A. ; Quon, Harry ; Kilger, A. ; Sherman, E. ; Weinstein, G. ; Chalian, A. ; Poptani, H. / Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. In: American Journal of Neuroradiology. 2010 ; Vol. 31, No. 2. pp. 262-268.
@article{523b059bd2364b068ba1d298021eba6d,
title = "Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging",
abstract = "BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of Ktrans, ve, and τi. Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment Ktrans value of the CR group (0.64 ± 0.11 minutes-1, n = 24) was significantly higher (P = .001) than that of the PR (0.21 ± 0.05 minutes-1, n = 9) group. No significant difference was found in other pharmacokinetic model parameters: ve and τi, between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P = .276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC.",
author = "Sungheon Kim and Loevner, {L. A.} and Harry Quon and A. Kilger and E. Sherman and G. Weinstein and A. Chalian and H. Poptani",
year = "2010",
month = "2",
doi = "10.3174/ajnr.A1817",
language = "English (US)",
volume = "31",
pages = "262--268",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "2",

}

TY - JOUR

T1 - Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging

AU - Kim, Sungheon

AU - Loevner, L. A.

AU - Quon, Harry

AU - Kilger, A.

AU - Sherman, E.

AU - Weinstein, G.

AU - Chalian, A.

AU - Poptani, H.

PY - 2010/2

Y1 - 2010/2

N2 - BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of Ktrans, ve, and τi. Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment Ktrans value of the CR group (0.64 ± 0.11 minutes-1, n = 24) was significantly higher (P = .001) than that of the PR (0.21 ± 0.05 minutes-1, n = 9) group. No significant difference was found in other pharmacokinetic model parameters: ve and τi, between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P = .276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC.

AB - BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of Ktrans, ve, and τi. Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment Ktrans value of the CR group (0.64 ± 0.11 minutes-1, n = 24) was significantly higher (P = .001) than that of the PR (0.21 ± 0.05 minutes-1, n = 9) group. No significant difference was found in other pharmacokinetic model parameters: ve and τi, between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P = .276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=76749085256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749085256&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A1817

DO - 10.3174/ajnr.A1817

M3 - Article

VL - 31

SP - 262

EP - 268

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 2

ER -